| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2017: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2015: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we showed that glycolysis enzymes GAPDH, Enolase, PKM 2 inhibit HIV-1 replication. In particular, GAPDH and PKM 2 inhibited HIV-1 replication by inhibiting packaging of tRNALys3, a reverse transcriptase primer, into viral particles. Moreover, we demonstrated that the uncoating process of HIV-1 is suppressed by FDA-approved Trametinib. These findings are useful for the development of a more effective anti-HIV strategy.
|
